It is our intention to pursue prospective targets that are focused on healthcare innovation. We anticipate targeting companies domiciled in North America, Europe and Asia that are developing assets in the biopharmaceutical and, medical technology/medical device space, which aligns with our management team’s experience in operating healthcare companies and in drug and device/technology development. 

(Note: Isleworth Healthcare Acquisition upsized its SPAC IPO on Feb. 24, 2021, at pricing: 18 million units, up from 15 million in the prospectus, at $10 each to raise $180 million.)